{"organizations": [], "uuid": "1e6356c3ed45b19cf9627a32fe2cfc6b85ce597d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/07/globe-newswire-immune-design-to-report-fourth-quarter-and-year-end-2017-financial-results-and-provide-corporate-update.html", "country": "US", "domain_rank": 767, "title": "Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T16:00:00.000+02:00", "replies_count": 0, "uuid": "1e6356c3ed45b19cf9627a32fe2cfc6b85ce597d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/07/globe-newswire-immune-design-to-report-fourth-quarter-and-year-end-2017-financial-results-and-provide-corporate-update.html", "ord_in_thread": 0, "title": "Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update", "locations": [], "entities": {"persons": [], "locations": [{"name": "south san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report fourth quarter and year end 2017 financial results after the close of U.S. financial markets on Wednesday, March 14, 2018. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on March 14, 2018 to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 3777048.\nAbout Immune Design\nImmune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex ® and GLAAS ® . Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com .\nMedia Contact\nJulie Rathbun\nRathbun Communications\njulie@rathbuncomm.com\n206-769-9219\nInvestor Contact\nSylvia Wheeler\nSylvia.wheeler@immunedesign.com\nSource:Immune Design Corp.", "external_links": ["https://www.globenewswire.com/Tracker?data=vQ59QcVIgJsG1BKZUpKh7S518dxGZ7qDB4fRODqIwiZSwOYLkvIgmjYVm2XT9S7YkD3P8vdP_6g9UYE2RCAAWwyDmmKWjczCf5qxZd2n8CA=", "https://www.globenewswire.com/Tracker?data=ZVTL50ta3K8_eGVV_azuR8paC7wDeee1OU8Dfut74gUfeDbi44KggJDRfMx_twLYpNoEh0ueUAjyMh9RBFFYVCuJeBplkiljLK1vCRSXMNOLRbk94jZR1Z0a2tr17yNe", "https://www.globenewswire.com/Tracker?data=O4PFcuJujjazpN6sp2cY7XQRDAgSaJKxAvupa2hWtWh1k-k0s2e7OosrfoqUD5vxlU6icgfKgqMEzAeyJcqcRy8rThdfRNO-za13PqrAk10=", "https://www.globenewswire.com/Tracker?data=ZhBAt7GbU2nTHOXCo9_UAsJJrSAxdh-8RK6VAQ2VcAD4TSKx__l6S5m8nPY1dbia-BVNslHhhLNkIvVOv5rs6cq974iVCD0Sfv10aj2EjAIIDZGOjMb1HRpIxFQdJeZq", "http://ir.immunedesign.com/events.cfm", "https://www.globenewswire.com/NewsRoom/AttachmentNg/1207fa05-a6ad-4e7c-a2ce-b72badbc5bb7"], "published": "2018-03-07T16:00:00.000+02:00", "crawled": "2018-03-07T18:58:19.002+02:00", "highlightTitle": ""}